Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.

Saved in:

Bibliographic Details
Title:	Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.
Authors:	Canonici A; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Browne AL; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Ibrahim MFK; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Fanning KP; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Roche S; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Conlon NT; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., O'Neill F; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Meiller J; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Cremona M; Medical Oncology Group, Department of Molecular Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland., Morgan C; Medical Oncology Group, Department of Molecular Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland., Hennessy BT; Medical Oncology Group, Department of Molecular Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland., Eustace AJ; National Institute for Cellular Biotechnology, Dublin City University, Whitehall, Glasnevin, Dublin 9, Ireland., Solca F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., O'Donovan N; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Crown J; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
Source:	Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2020 Jan 28; Vol. 12, pp. 1758835919897546. Date of Electronic Publication: 2020 Jan 28 (Print Publication: 2020).
Publication Type:	Journal Article
Journal Info:	Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1758-8340
DOI:	10.1177/1758835919897546